TGFB1 and systemic sclerosis: In sclerotic stage, SSc dermal fibroblasts are constitutively activated with the pro-fibrotic phenotype quite similar to that of normal fibroblasts treated with TGF-β1 even though the expression of TGF-β is weak or undetectable in the skin [41].